Technology

Can-Fite Submits First Piclidenoson Phase 2 Protocol for Lowe Syndrome

Published

Courtroom-sketch editorial illustration of the historic arched Bambino Gesù Children’s Hospital campus in Rome, viewed from the street with its stairway, stone walls, parked cars and pedestrians.

Can-Fite BioPharma submitted a Phase 2 protocol to Bambino Gesù Children’s Hospital in Rome for the first clinical evaluation of Piclidenoson in patients with Lowe syndrome. The open-label, single-center study will give oral Piclidenoson twice daily for six months to five adults with genetically confirmed disease. Its primary endpoint measures improvement in renal uptake of 99mTc-DMSA, with secondary measures covering tubular-function biomarkers, Fanconi syndrome parameters and safety. Can-Fite said preclinical studies found restoration of OCRL-dependent cellular function; Lowe syndrome currently has no approved disease-modifying therapy.

Sources

Primary sources:123

Related stories

  1. Bloom Security Raises $20 Million Seed Round for AI-Native Endpoint Protection
  2. Deel Acquires Israeli Deepfake-Detection Startup Clarity
  3. Haifa-Tel Aviv High-Speed Rail Expansion Wins Committee Approval
  4. Phoenix Invests NIS 234 Million in PowerGen at NIS 3.25 Billion Valuation
  5. Tal Inbar Named Apple Israel CEO as Rony Friedman Takes Global Chip-AI Role

Something went wrong

We couldn't complete that action. Check your connection and try again.